HOME > BUSINESS
BUSINESS
- Maruho, Galderma Give Update on Their Comprehensive Collaboration
July 21, 2016
- Hiroki Kitamura Picked as New Yoshindo President
July 21, 2016
- 38% of Complete Response Patients Remained in Remission for 5-Plus Years: Adcetris PII
July 20, 2016
- US FDA OKs Once-Daily Belviq: Eisai
July 20, 2016
- FDA, EMA Accept Opdivo Filing for Head and Neck Cancer
July 20, 2016
- Bayer, Taisho Join Hands on Switch OTC Version of Claritin
July 19, 2016
- Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan
July 15, 2016
- AnGes MG, Osaka Univ. Team Up for Joint Research on Novel Drug Delivery System
July 15, 2016
- Takeda Launches Awareness Campaign for Inflammatory Bowel Disease in Europe, US
July 14, 2016
- Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University
July 14, 2016
- SymBio Earns Sales Milestone for Bendamustine from Taiwanese Firm
July 13, 2016
- “Limited Potential for Growth through Domestic Business Alone” Is Reason for Acquiring US Generic Maker: Nichi-Iko Pres.
July 13, 2016
- AnGes MG to Develop Chimera Decoy for World’s 1st Simultaneous Inhibition of Multiple Targets as Anti-Inflammatory Therapies
July 13, 2016
- Ono Gets Rights to Celyad’s Allogeneic CAR T-cell Therapy
July 12, 2016
- Kyorin to Copromote Allergy Drug Desloratadine with Kaken
July 12, 2016
- Medreich’s Japan-Bound Generics Plant in India Completed: Meiji
July 12, 2016
- Nichi-Iko to Buy Sagent for US$736 Million
July 12, 2016
- 1st Patients Randomized in PII Cell Therapy Trial for Traumatic Brain Injury: SanBio
July 12, 2016
- Ethical Drug Sales Up 5.8% in May: Crecon Report
July 12, 2016
- Kyorin Eager to Resurrect Drug Discovery Prowess, Says President
July 11, 2016
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
